RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

There has been exciting animal data for high-impact AMPA modulators before (e.g. Lilly and Parkinson's, 2002; Cortex and Huntington's 2008) but no one is going to get overly generous when it has been safety that has cropped up several times for earlier iterations on the theme.

So any high-impact licensing deal would be backend-loaded--a few million up front at best, everything else comprised of eventual milestones. 2007-9: I have four CNS partnerships at preclinical stage (a lead compound, some animal efficacy data): Two didn't even have the upfront amount separated out from 'total milestones possible', which means a million or two; one was $3 million upfront, the best was a Merck/Addex deal, $22 million upfront, mGluR and schizophrenia. That last one is the exception, not the rule.

NeuroInvestment